• 1
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 11171130. Erratum in: Am J Hum Genet. 2003; 73: 709.
  • 2
    Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676689.
  • 3
    Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol. 2005; 23: 16561663.
  • 4
    Rimer BK, Bluman LG. The psychosocial consequences of mammography. J Natl Cancer Inst Monogr. 1997: 131138.
  • 5
    Rijnsburger AJ, Essink-Bot ML, van Dooren S, et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer. 2004; 91: 6976.
  • 6
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 7
    Kramer JL, Velazquez IA, Chen BE, et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005; 23: 86298635.
  • 8
    Madalinska JB, Hollenstein J, Bleiker E, et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005; 23: 68906898.
  • 9
    Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001; 93: 16331637.
  • 10
    Julian-Reynier CM, Bouchard LJ, Evans DG, et al. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer. 2001; 92: 959968.
  • 11
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA-1 mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995; 56: 256271.
  • 12
    Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 2: 10551062.
  • 13
    Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005; 6166.
  • 14
    van Oostrom I, Meijers-Heijboer H, Lodder LN, et al. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003; 21: 38673874.
  • 15
    Wagner TM, Moslinger R, Langbauer G, et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer. 2000; 82: 12491253.
  • 16
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003; 21: 16751681.
  • 17
    Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev. 2004; 13: 19891995.
  • 18
    Stolier AJ, Corsetti RL. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Am Surg. 2005; 71: 10311033.
  • 19
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 16091615.
  • 20
    Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer. 2002; 38 suppl 6: S15S17.
  • 21
    Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005; 23: 74917496.
  • 22
    Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer. 2005; 118: 22812284.
  • 23
    King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286: 22512256.
  • 24
    Port ER, Montgomery LL, Heerdt AS, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001; 8: 580585.
  • 25
    Metcalfe KA, Snyder C, Seidel J, et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2005; 4: 97103.
  • 26
    Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997; 277: 9971003.
  • 27
    Shah SK, Greatrex KV. Current role of magnetic resonance imaging in breast imaging: a primer for the primary care physician. J Am Board Fam Pract. 2005; 18: 478490.
  • 28
    Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol. 2001; 19: 35243531.
  • 29
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23: 84698476.